Prevacid struggles

Abbott/TAP joint venture readjusts 2004 sales expectations due to a reported 7% year-to-date decline in the Rx PPI market. Prilosec OTC has "probably had more of an impact on the branded side than anticipated, or at least the impact has lasted longer," says Abbott Divisional VP-Investor Relations John Thomas in a July 9 earnings call. TAP now expects full-year Prevacid sales to decrease by around 10%, according to Abbott, and will attempt to reinvigorate the brand by targeting adolescents and launching new formulations such as the recently approved Prevacid SoluTab Orally Disintegrating Tablets. SoluTabs provide "flexibility and convenience, especially in children and other patients that have difficulty swallowing," states Abbott VP-Investor Relations & Public Affairs Catherine Babington. The firm expects the branded PPI market will grow "at a more modest rate" in the second half of 2004...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

US FDA Could Miss User Fee Spending Triggers With House FY 2026 Funding

 

FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user free appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.

PCMA, CVS, Cigna File Lawsuits Over ‘Dangerous’ Arkansas PBM Law

 
• By 

The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.

Medicare Part D LIS Access Threatened By House Budget Bill’s Medicaid Obstacles

 
• By 

An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.